In a groundbreaking development, Porton Advanced has recently unveiled a strategic collaboration with Ascle Therapeutics, aimed at advancing the joint development and production of Natural Killer (NK) cells. The partnership is set to catalyze progress in the area of gene and cell therapy, propelling the application of NK cells into multifaceted domains such as cancer prevention, beauty, and anti-aging.
Porton Advanced, an industry leader dedicated to providing comprehensive Contract Development and Manufacturing Organization (CDMO) services in gene and cell therapy, has a proven track record in successfully guiding customers through the complexities of multiple gene and cell therapy drugs. This encompasses diverse areas such as plasmids, cell therapy, gene therapy, and mRNA therapy. On the other hand, Ascle Therapeutics specializes in pioneering research and production of revolutionary immune cell therapy products, particularly focusing on the NK/CAR-NK anti-tumor immune cell therapy drugs.
Under the terms of the agreement, Porton Advanced will extend its services to include development, production, and regulatory declaration in China for Ascle Therapeutics’ NK cell project. This collaborative effort is poised to provide robust support for the application of NK cells in cancer prevention, anti-aging, and beauty.
Dr. Li Huashun, the founder and chairman of Ascle Therapeutics, emphasized the transformative potential of CAR-NK cell therapy in cancer treatment. By employing genetic engineering to enhance the ability of NK cells to identify and eliminate tumor cells while minimizing harm to normal cells, CAR-NK cell therapy presents significant advantages in the treatment of solid tumors. Dr. Li also highlighted the remarkable efficacy of NK cells in anti-aging, revealing that a single dose of two billion young and healthy cells can substantially reduce senescent cells in circulation, with effects lasting from 3 to 18 months.
Expressing enthusiasm about the partnership, Dr. Wang Yangzhou, CEO of Porton Advanced, highlighted the depth of Ascle Therapeutics’ research and development pipeline, particularly in the NK cell field. Dr. Wang emphasized Porton Advanced’s end-to-end gene and cell therapy CDMO platform, equipped with exceptional process development capabilities and state-of-the-art sterile drug production workshops. This platform, combined with international production, inspection, and release standards, positions Porton Advanced as a pivotal collaborator, ready to support Ascle Therapeutics in advancing NK cell applications in anti-aging, beauty, and cancer prevention.
The collaborative venture is poised to leverage the strengths of both entities, combining Ascle Therapeutics’ profound expertise in NK cells with Porton Advanced’s extensive experience in gene and cell therapy. The aspiration is to not only advance the development and production of NK cells but also to ensure their seamless integration into diverse therapeutic and cosmetic applications, marking a significant stride forward in the fields of healthcare and aesthetics.